| Literature DB >> 36160768 |
Tai-Xiang Liu1, Li-Zhong Du1, Xiao-Lu Ma1, Zheng Chen1, Li-Ping Shi1.
Abstract
Background: Omphalocele is a common congenital defect of the abdominal wall, management of giant omphalocele (GO) is particularly for pediatric surgeons and neonatologists worldwide. The current study aimed to review and summarize the clinical features and prognosis in neonates with GO complicated with pulmonary hypertension (PH), which is associated with increased mortality, while in hospital. Materials and methods: Medical records of infants with GO between July 2015 and June 2020 were retrospectively analyzed. The patients enrolled were divided into PH and non-PH groups based on the presence or absence of PH, and patients with PH were divided into death and survival groups based on survival status. Clinical characteristics and outcomes were compared between groups, respectively. The risk factors for PH were analyzed by binary logistic regression.Entities:
Keywords: giant omphalocele; infants; neonates; omphalocele; pulmonary hypertension
Year: 2022 PMID: 36160768 PMCID: PMC9505988 DOI: 10.3389/fped.2022.940289
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
FIGURE 1Flowchart of participants.
Comparison of the baseline characteristics of the study cohort by the presence of PH.
| Variables | PH group ( | Non-PH group ( | |
| Male gender | 16 (66.7%) | 20 (46.5%) | 0.113 |
| Gestational age (wk) | 38 (36.3–38.3) | 38 (36.1–38.7) | 0.942 |
| Birth weight (g) | 2834 ± 690 | 2693 ± 581 | 0.378 |
| SGA | 2 (8.3%) | 7 (16.3%) | 0.589 |
| Perinatal asphyxia | 8 (33.3%) | 6 (14%) | 0.061 |
| Intubation within 24 h after birth | 6 (25%) | 2 (4.7%) | 0.038 |
| Solid organ in the sac | 24 (100%) | 43 (100%) | NA |
| Hollow organ in the sac | 19 (79.2%) | 27 (62.8%) | 0.166 |
| Respiratory system abnormalities | 21 (87.5%) | 27 (62.8%) | 0.031 |
| Pulmonary hypoplasia | 21 (87.5%) | 26 (60.5%) | 0.020 |
| Tracheal bronchus | 2 (8.3%) | 0 (0%) | 0.125 |
| Vascular loop | 2 (8.3%) | 0 (0%) | 0.125 |
| Diaphragmatic hernia and eventration | 2 (8.3%) | 1 (2.3%) | 0.290 |
| Digestive system abnormalities | 20 (83.3%) | 32 (74.4%) | 0.401 |
| Intestinal malrotation | 20 (83.3%) | 29 (67.4%) | 0.159 |
| Meckel’s diverticulum | 3 (12.5%) | 4 (9.3%) | 0.695 |
| Gallbladder agenesis | 2 (8.3%) | 3 (7%) | >0.999 |
| Mesenteric hiatal hernia | 0 (0%) | 1 (2.3%) | >0.999 |
| Urogenital system abnormalities | 6 (25%) | 4 (9.3%) | 0.149 |
| Indirect inguinal hernia | 5 (20.8%) | 3 (7%) | 0.124 |
| Cryptorchidism | 2 (8.3%) | 2 (4.7%) | 0.614 |
| Beckwith-wiedemann syndrome | 1 (4.2%) | 1 (2.3%) | >0.999 |
| PDA | 7 (29.2) | 3 (7%) | 0.028 |
| Age at surgery (d) | 2 (2–5) | 2 (1–3) | 0.144 |
| Staged operation | 7 (29.2) | 1 (2.3) | 0.002 |
IQR, interquartile range; PDA, patent ductus arteriosus; PH, pulmonary hypertension; SD, standard deviation; SGA, small for gestational age; NA, not applicable. *Represents statistically significant, p < 0.05.
Logistic regression analysis of risk factors of GO-associated PH.
| Variable | β | OR | 95% CI | |
| Staged operation | 2.850 | 0.010 | 17.294 | 1.975–151.424 |
| Constant | –0.904 | 0.002 | 0.405 |
CI, confidence interval; GO, giant omphalocele; OR, odds ratio; PH, pulmonary hypertension. *Represents statistically significant, p < 0.05.
Comparison of clinical outcomes of the study cohort by the presence of PH.
| Variables | PH group ( | Non-PH group ( | |
| Duration of mechanical ventilation (days) | 11 (5–42) | 3 (1–6) | <0.001 |
| Oxygen requirement days (days) | 39 (21–62) | 15 (6–31) | <0.001 |
| Requirement for supplemental oxygen at home | 5 (20.8%) | 3 (7%) | 0.065 |
| PN days (days) | 31 (22–48) | 14 (10–19) | <0.001 |
| Nasal feeding home | 1 (4.2%) | 1 (2.3%) | >0.999 |
| Length of NICU stay (days) | 28 (14–51) | 11 (8–20) | 0.001 |
| Length of hospital stay (days) | 40 (24–65) | 19 (15–29) | 0.002 |
| Death | 8 (33.3%) | 1 (2.3%) | 0.001 |
IQR, interquartile range; NICU, neonatal intensive care unit; PH, pulmonary hypertension; PN, parenteral nutrition. *Represents statistically significant, p < 0.05.
Clinical characteristics of death and survival groups in infants with PH.
| Death group ( | Survival group ( | ||
| Gestational age (wk) | 37 (32.7–38.1) | 38 (37.5–38.6) | 0.114 |
| Birth weight (g) | 2379 ± 787 | 3061 ± 525 | 0.019 |
| Intubation within 24 h after birth | 3 (37.5%) | 3 (18.8%) | 0.362 |
| Time of diagnosis of PH (days) | 8 (1–78) | 5 (3–7) | 0.516 |
| PH diagnosed within 7 days after birth | 4 (50%) | 12 (75%) | 0.363 |
| PASP (mmHg) | 86.4 ± 21.7 | 61.3 ± 15.4 | 0.003 |
| Systolic SBP (mmHg) | 76.5 ± 9.9 | 71.3 ± 7.1 | 0.152 |
|
| |||
| Single type of PVD | 0 (0%) | 4 (25%) | 0.273 |
| Two types of PVD | 3 (42.9%) | 7 (43.8%) | >0.999 |
| Three or more types of PVD | 4 (57.1%) | 5 (31.3%) | 0.363 |
|
| |||
| Improvement | 3 (42.9%) | 16 (100%) | 0.004 |
| Ineffectiveness | 4 (57.1%) | 0 (0%) | 0.004 |
| Duration of PVD (days) | 21 ± 36 | 38 ± 28 | 0.257 |
| PDA | 2 (25%) | 5 (31.3%) | >0.999 |
| PDA ligation | 0 (0%) | 4 (25%) | 0.262 |
IQR, interquartile range; PASP, pulmonary arterial systolic pressure; SBP, systemic blood pressure; PDA, patent ductus arteriosus; PH, pulmonary hypertension; PVD, pulmonary vasodilators; SD, standard deviation. *Represents statistically significant, p < 0.05.